Related Experiment Video
Updated: May 18, 2026
05:07
A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration
Published on: August 2, 2024
Recent advances in pharmacotherapy development for abdominal aortic aneurysm
Koichi Yoshimura1, Hiroki Aoki
1Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755-8505, Japan.
International Journal of Vascular Medicine
|September 8, 2012
Summary
Abdominal aortic aneurysm (AAA) pharmacotherapy is lacking. Targeting c-Jun N-terminal kinase (JNK) shows promise for AAA treatment by restoring extracellular matrix balance.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Abdominal aortic aneurysm (AAA) is a life-threatening condition with limited nonsurgical treatment options.
- Inflammatory pathways and extracellular matrix (ECM) degradation are key drivers of AAA pathogenesis.
- c-Jun N-terminal kinase (JNK) signaling is implicated in AAA development and progression.
Purpose of the Study:
- To investigate JNK as a therapeutic target for abdominal aortic aneurysm (AAA).
- To evaluate the potential of pharmacologic JNK inhibition in restoring ECM balance.
- To explore strategies for developing clinically applicable AAA pharmacotherapy.
Main Methods:
- Identification of JNK as a critical signaling molecule in AAA tissue.
- Experimental models demonstrating the role of JNK in regulating ECM metabolism.
- Assessment of pharmacologic JNK inhibition effects on AAA pathology.
Main Results:
- Abnormal JNK activation in AAA tissue promotes pathological processes.
- Inhibition of JNK shifts ECM balance from degradation toward repair.
- Targeting JNK may offer a coordinated approach to manipulate multiple AAA pathological processes.
Conclusions:
- JNK is a viable therapeutic target for abdominal aortic aneurysm (AAA) pharmacotherapy.
- Pharmacologic inhibition of JNK can reverse ECM degradation and promote repair.
- Development of biomarkers and drug delivery systems is crucial for clinical translation.
More Related Videos
Related Concept Videos
01:26Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...